中国男性乳腺癌患者治疗策略的变化：单中心 40 年经验

Changes in therapeutic strategies in Chinese male patients with breast cancer: 40 years of experience in a single institute.

机构信息

State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, PR China.

出版信息

Breast. 2010 Dec;19(6):450-5. doi: 10.1016/j.breast.2010.04.007. Epub 2010 May 21.

DOI:10.1016/j.breast.2010.04.007

PMID:20494580

Abstract

The changes in therapeutic strategies were determined and the efficacy of radical mastectomy (RM) and modified radical mastectomy (MRM) on Chinese male breast cancer (MBC) patients was compared. Seventy MBC patients, with a median age of 61 years, were enrolled. The characteristics of MBC were compared in cohort A (1969-1997) and cohort B (1998-2009), and the prognosis was compared between the RM and MRM groups. Infiltrating ductal carcinoma accounted for 81.4% of all cases; 93.7% were estrogen receptor (ER)/progesterone receptor (PR)-positive. More patients in cohort B accepted multidisciplinary treatment, MRM, adjuvant chemotherapy, and endocrine therapy than those in cohort A; however, the 5-year overall survival rates were similar in the two cohorts. The overall survival curves, locoregional recurrence rates, and systematic metastatic rates were similar in the RM and MRM groups. Currently, more MBC patients receive conservative surgery; MRM may be equally effective as RM for MBC.

摘要

研究比较了中国男性乳腺癌（MBC）患者根治性乳房切除术（RM）和改良根治性乳房切除术（MRM）的疗效，并确定了治疗策略的变化。共纳入 70 例中位年龄 61 岁的 MBC 患者。在队列 A（1969-1997）和队列 B（1998-2009）中比较了 MBC 的特征，并比较了 RM 和 MRM 组的预后。所有病例中浸润性导管癌占 81.4%；93.7%的患者雌激素受体（ER）/孕激素受体（PR）阳性。与队列 A 相比，队列 B 中有更多的患者接受了多学科治疗、MRM、辅助化疗和内分泌治疗；但两组的 5 年总生存率相似。RM 和 MRM 组的总生存曲线、局部区域复发率和系统转移率相似。目前，更多的 MBC 患者接受了保守手术；MRM 可能与 RM 一样对 MBC 有效。